Celyad VP On IP Issues, Development Timelines For CAR-T Therapies
Georges Rawadi, vice president of business development and intellectual property at Celyad, talks to Scrip on the sidelines of the recent BIO-Europe Spring partnering conference in Barcelona about the company's pipeline of CAR-T therapies and recently resolved patent disputes for its technology.
You may also be interested in...
New strategies to overcome safety, solid tumor and other challenges associated with CAR-T therapies – and some early clinical data for patients treated with Poseida's, Celyad's and Autolus' novel products – were featured at the American Association for Cancer Research (AACR) meeting.
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.